Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

Trial Details

NCT ID
NCT06974110
Phase
PHASE1
Sponsor
MOMA Therapeutics
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • MOMA-341
  • Irinotecan
  • Immunotherapy
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • Tampa, Florida, United States|27.94752,-82.45843
  • Detroit, Michigan, United States|42.33143,-83.04575
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Raleigh, North Carolina, United States|35.7721,-78.63861

Key Eligibility Criteria

  • Age ≥ 18 years
  • Participants have unresectable advanced or metastatic solid tumors with MSI-H or dMMR alterations and histologically confirmed disease. Participant…
  • Have at least 1 lesion at baseline (measurable or non-measurable) suitable for repeat imaging evaluation by RECIST and/or PCWG-3
  • ECOG PS ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →